Eli Lilly reported strong recent financial results with solid revenue growth and robust margins, even raising its guidance. However, signs of slowing revenue growth in the near future could impact margins and temper enthusiasm. Despite this, Eli Lilly's attractive market valuation still supports a Buy rating, though less compelling than in previous months. Investors should watch for potential risks as growth momentum cools.
Eli Lilly trades at USD 1,411.20 on Pluang as of Nov 03, 2026 05:11 WIB, down 0.45% in one day. The stock holds a market cap of $1.26 trillion and a dividend yield of 0.49%. Pluang order activity shows 80% of investors buying and 20% selling, reflecting steady interest despite growth concerns.
Eli Lilly, having reached a $1.146 trillion market cap largely due to weight-loss drugs Mounjaro and Zepbound, is now showing strong growth potential in oncology, immunology, and neuroscience sectors, with Q2 revenue from these areas up 121% year ove...
Eli Lilly reported strong third-quarter results with a 39% increase in revenue to $24.4 billion, fueled by successful drug franchises like Mounjaro and Zepbound. The company’s growth is becoming more diversified with new products such as Foundayo, Re...
Eli Lilly's stock surged 6% to a record $1.3 trillion valuation after reporting stronger-than-expected earnings driven by sales of weight-loss drugs Mounjaro and Zepbound. Both drugs exceeded sales expectations by over 5%, reinforcing Eli Lilly's dom...
Eli Lilly reported a 38.6% year-over-year revenue increase to $24.4 billion in Q3, driven by strong sales of its diabetes and obesity treatments Mounjaro and Zepbound, which generated $16.08 billion, up 59.1% from last year. Sales of Ebglyss, a treat...
Merck's stock rose 5% following its Q3 2026 earnings report, which beat analyst expectations with adjusted EPS of $2.49 and revenue of $18.09 billion. The company raised its 2026 adjusted EPS guidance to $2.77-$2.82, driven by strong sales of its can...
